News

Dechra Announces VOHC Acceptance for Water Additive

Dechra Veterinary Products is pleased to announce that its VETRADENT^® Liquid Water Additive has received the seal of acceptance to Help Control Tartar from the Veterinary Oral Health Council (VOHC). The seal has been granted for dogs after properly demonstrating both safety and efficacy.

Dechra acquires the rights to Malaseb^®

Dechra is pleased to announce the licensing rights of the Malaseb^® brand of dermatology products in the United States with Dermcare of Australia.

Dechra acquires the rights to Laverdia™-CA1 (verdinexor tablets)

Dechra Veterinary Products is pleased to announce that Dechra has acquired the rights to Laverdia™-CA1 (verdinexor tablets) from Anivive Lifesciences, Inc.

Dechra acquires Isoflurane and Sevoflurane from Halocarbon Life Sciences

Dechra is pleased to announce the acquisition of the veterinary approved Isoflurane^®, USP Inhalant Anesthetic and Sevoflurane^®, USP Inhalant Anesthetic from Halocarbon.

Dechra announces partnership with Bioiberica to boost companion animal offering in the United States

Dechra is pleased to announce a joint collaboration with Bioiberica, a global Life Science company committed to improving the health and well-being of people, animals and plants, for the license and distribution of its Atopivet® range of dermatology products for cats and dogs in the United States.

DSM Biomedical and Dechra partner to fuel innovation in animal injury recovery

DSM Biomedical announces a joint collaboration with Dechra Limited for the license and distribution of devices that create isolated solutions of highly concentrated cells and / or platelets for use with horses and companion animals.

Dechra acquires Sucromate™ Equine (deslorelin acetate) sterile suspension from Thorn Bioscience L.L.C

This acquisition expands Dechra’s equine portfolio in the reproductive category.

Dechra receives approval for Amoxicillin and Clavulanate Potassium Oral Suspension Drops

Approval expands Dechra’s growing companion animal products (CAP) range of anti-infectives.

Dechra Acquires Rompun® (xylazine injection) 100mg/ml and Butorphanol Tartrate Injection 10mg/ml from Elanco™ Animal Health

Acquisition expands Dechra’s equine portfolio into the anesthesia and analgesia category.

Dechra Acquires Exclusive License from Hassinger Biomedical for Equine ProVet APC™

Dechra Veterinary Products is pleased to announce the acquisition of the veterinary marketing and distribution rights to the ProVet APC™ (Autologous Platelet Concentrate) and ProVet BMC™ (Bone Marrow Concentrate) systems from Hassinger Biomedical. These two patented medical devices concentrate platelets or bone marrow in 90 seconds with a processing time of 2.5 minutes from start to finish.